logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

We Highlight Breast Cancer Awareness Month

Our ADC Franchise is developing two assets for the treatment of metastatic breast cancer utilizing our proprietary ADC technology.

October 2018 - Breast cancer is the second most common cancer worldwide, and accounts for approximately 1.67 million of 14.1 million new cases of cancer diagnosed each year.1,2 Despite improving survival rates over the past 50 years, breast cancer was the fifth leading cause of cancer death overall.1,4

Metastatic breast cancer very difficult to treat

The most advanced form of breast cancer is metastatic (also called Stage 4) breast cancer - meaning the disease has spread from the breast to other parts of the body such as the lungs, liver, bones or brain.4 Approximately six percent of new breast cancer diagnoses are classified as metastatic.5 This kind of cancer is more difficult to treat and tends to have a worse prognosis than earlier stages of the disease. Women with metastatic breast cancer have a 5-year relative survival rate of about 22 percent.6 Making strides to advance our proprietary ADC linker and payload technologies to potentially potentially bring additional treatment options to women living with advanced or metastatic breast cancer is exactly the focus of our ADC Franchise!

This year, Breast Cancer Awareness month will come to life through many diverse organizations around the world. We are right in the middle of health clinics, professional societies, academic institutions and patient groups to raise awareness. As we are proud to be on the frontlines of research and development to explore potential new metastatic breast cancer treatments our focus is on highlighting the urgent need for action.

1 Ferlay J, et al. J Cancer. 2015;136(5): E359-86.

2 Ferlay J, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide; IARC CancerBase No.11. 2013.

3 Metastatic Breast Cancer Network. What is Metastatic Breast Cancer? 2017.

4 Sledge, et al. J Clin Oncol. 2014; 32:1-8.